Developing oral anti-virals for COVID-19 and other Pan-coronaviruses.
| Year | Firm | Period | Expenses | Doc |
|---|---|---|---|---|
| 2022 | PARDES BIOSCIENCES, INC. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$120,000 | |
| 2022 | PARDES BIOSCIENCES, INC. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$120,000 | |
| 2022 | PARDES BIOSCIENCES, INC. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$120,000 | |
| 2022 | PARDES BIOSCIENCES, INC. |
1st Quarter (Jan 1 - Mar 31) AMENDED |
$120,000 | |
| 2022 | PARDES BIOSCIENCES, INC. |
1st Quarter (Jan 1 - Mar 31) Registration |
— |
| Firm | Filings | Expenses |
|---|---|---|
| PARDES BIOSCIENCES, INC. | 7 | $720,000 |
| Issue | Activities |
|---|---|
| Health Issues | 7 |
| Medicare/Medicaid | 7 |
| Pharmacy | 7 |
| Medical/Disease Research/Clinical Labs | 7 |